A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 106, Issue 1, 2006, Pages 34-42

  Stamenova, P ^a   Koytchev, R ^a   Kuhn, K ^a   Hansen, C ^a   Horvath, F ^a   Ramm, S ^a   Pongratz, D ^a  

^a NONE

Author keywords

Placebo; Randomized controlled trial; Spasticity; Stroke; Tolperisone

Indexed keywords

CENTRAL MUSCLE RELAXANT; TOLPERISONE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE TONE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SPASTICITY; TREATMENT OUTCOME;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; MUSCLE TONUS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TOLPERISONE; TREATMENT OUTCOME;

EID: 33644851242     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bakheit A.M.O, Thilman A.F., Ward A.B. et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
2. Bass B., Weinshenker B., Rice G.P. et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15:15-19.
3. Bes A., Eyssette M., Pierrot-Deseilligny E. et al. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709-718.
4. Bohannon R.W., Smith M.B. Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther 1987;67:206-207.
5. Dictz V. Syndrom der spastischen Parese. Aktuelle Neurol 2001;28:49-52.
6. Dulin J., Kovacs L., Ramm S. et al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 1998;31:137-142.
7. Emre P. New development in the medical treatment of spasticity. In: Spasticity: Mechanisms and Management. Eds. A.F. Thilmann, D.J. Burke, W.Z. Rymer. Berlin-Heidelberg-New York: Springer 1993;372-384.
8. Farkas S., Gere A. Pharmacology of Tolperisone (Mydocalm). Studies on the Mechanism of Action. Gedeon Richter Ltd, Company Report RGD 47012, 1994.
9. Feher M., Juvancz P., Szontagh M. Effect of Mydocalm in the rehabilitation of hemiparesis. Balneologia Rehailitdcio Gyogyfurdougy 1985;6:201-205.
10. Gracies J.M., Elovic E., McGuire J., Simpson D. Traditional pharmacological treatments for spasticity part II: general and regional treatments. Muscle Nerve 1997;6:Suppl:92-120.
11. Groves L., Shellenberger M.K., Davis C.S. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15:241-251.
12. Haas B.M., Bergstrom E., Jamous A., Bennie A. The inter rater reliability of the original and of the modified Ashworth Scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord 1996;34:560-564.
13. Haque A., Hossain M., Khan J. K. et al. New findings and symptomatic treatment for neurolathyrism, a motor neuron disease in north west Bangladesh. Paraplegia 1994;32:570-572.
14. Hinderer S.R., Lehmann J.F., Price R. et al. Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 1990;69:311-317.
15. Hulme A., MacLennan W.J., Ritchie R.T. et al. Baclofen in the elderly stroke patient - its side-effects and pharmacokinetics. Eur J Clin Pharmacol 1985;29:467-469.
16. Katz R.T., Rovai G.P., Brait C., Rymer W.Z. Objective quantification of spastic hypertonia: correlation with clinical findings. Arch Phys Med Rehabil 1992;73:339-347.
17. Kohnen R., Krüger H.P., Dulin J. Die humanexperimentelle Unlersuchung sedierender Wirkungen von Medik-amenten im Zusammenwirken mit Alkohol. Psychologic 1995;21:768-775.
18. Lataste X., Emre M., Davies C., Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44:Suppl 9:53-59.
19. Medici M., Pebet M., Ciblis D. A double-blind, long-term study of tizanidine (Sirdalud) in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11:398-407.
20. Melka A., Haimanot R.T. Tolperisone HCl (Mydocalm): A Randomized Doubleblind and Placebo Controlled Drug Trial. International Conference on Lathyrus and Lathyrism. Ethiopia, Addis Abeba 1995;31-32 (book of abstracts).
21. Meythaler J.M., Guin-Renfroe S., Johnson A., Brunner R.M. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-1163.
22. Milanov I.G. Mechanisms of baclofen action on spasticity. Acta Neurol Scand 1992;85:305-310.
23. Miskolczi P., Vereczkcy L, Frenkl R. Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavarilability studies. Pharm Biomed Anal 1987;5:695-700.
24. O'Brien C.F., Seeberger L. C., Smith D.B. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 1996;9:332-340.
25. Ogawa N., Asanuma M., Hirata H. et al. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease. J Int Med Res 1992;20:78-86.
26. Ono H., Fukuda H., Kudo Y. Mechanism of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn 1984;7:171-176.
27. Ono H, Matsumoto K., Kato K. et al. Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol 1986;17:137-142.
28. Pratzel H.G., Alken R.G., Rainm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 1996;67:417-425.
29. Shah S., Vanclay F., Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989;42:703-709.
30. Sloan R.L., Sinclair E., Thompson J. et al. Inter-rater reliability of the modified Ashworth Scale for spasticity in hemiplegic patients. Int J Rehabil Res 1992;15:158-161.
31. Stien R., Nordal H.J., Oftedal S.I., Slettebo M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new antispastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987;75:190-194.
32. The United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44:Suppl 9:70-78.
33. Wallace J.D. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44:Suppl 9:60-69.
34. Wisscl J., Müller J., Dressnandt J. et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-49.